Acticor Biotech Announces Its Financial Calendar for the 1st Half of 2024
25.01.2024 - Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today its financial agenda for the 1st half of ...
United Kingdom Newton Biocapital Venture Investment European Medicines Agency French National Institute Of Health French National Institute
Source: wallstreet-online.de